Simplifying Global Compliance
Targacept Backpedals on TC-6987 After Data Analysis Error
Washington Drug Letter
Targacept’s asthma candidate TC-6987 met only one of its co-primary endpoints in a Phase II study, the company revealed April 10, placing the asthma indication on shakier ground than previously reported.
To View This Article:
Buy This Article Now
Copyright ©2017. All Rights Reserved.
Design, CMS, Hosting & Web Development :: ePublishing